Apotex Corp., a leading generic pharmaceutical company, announced that it has launched imatinib mesylate tablets the generic equivalent of Gleevec by Novartis.
"We are very excited to make a more affordable version of this important cancer medication available to the US market. It demonstrates our continued dedication to provide high quality, cost saving generic products to the US health care system," said Jeff Watson, president, Global Generics, Apotex Inc.
To increase availability to patients, Apotex has also developed an Imatinib Instant Savings Card.
Apotex's imatinib mesylate tablets are now available in 100mg and 400mg strengths. According to IMS Health, Gleevec had approximately $2.4 billion in sales in the 12 months ending in May 2016.
Launching imatinib mesylate tablets with the Imatinib Instant Savings Card is just another example of how Apotex is everywhere. Making a difference. One life at a time.
Apotex Inc. is the 7th largest generic pharmaceutical company globally (according to IMS Health) with over 10,000 employees and estimated sales of approximately $2 billion.